Skip to content
Intrinsic value · Buy/Sell verdict · scores — free· 500 Nifty 500 stocks· EOD 2026-06-15

Aster DM Healthcare Ltd.

ASTERDM · NSE · Healthcare

₹786.7
-28.25 (-3.47%)
Our verdict
Hold56/100
Quality55
Valuation18
Momentum84
Financial trend88
Intrinsic value
Our fair value
₹643.98
Overvalued by 18%
Price ₹786.7Range ₹421.57₹866.38

With a 20% margin of safety, our buy-below price is ₹515.18.

A
Financial health 100/100
Altman Z 9.11 · Safe zone

Piotroski F-score 5/9 — quality of earnings & balance sheet.

Investability checklist

Passed 8 of 13 checks62/100
  • ROE above 15%10.1%
  • Low debt (D/E < 0.5)0.46x
  • Positive free cash flow
  • Revenue growth > 10%18%
  • Earnings growing72%
  • Net margin ≥ 10%8.4%
  • Current ratio > 1.51.99
  • Below our fair value
  • Margin of safety ≥ 20%
  • Above 200-day average
  • Above 50-day average
  • Positive 1-year return
  • Altman Z in safe zoneZ 9.11
  • Piotroski ≥ 75/9

1-year price

EOD · 2026-06-15
1W
+2.7%
1M
+4.4%
3M
+15.5%
6M
+25.5%
1Y

Our scores

Durability55
Valuation16
Momentum84
Analyst consensus target ₹795.27 (+1%) · 11 analysts

Key fundamentals

Market cap
₹40,668 Cr
P/E ratio
122.2
P/B ratio
8.86
EPS (TTM)
₹6.44
ROE
10.1%
Debt / Equity
0.46x
Profit margin
8.4%
Free cash flow
₹1,347 Cr
52-week high
₹814.95
-3.47% from high
52-week low
₹535.6
Dividend yield
0.5%
Beta
-0.03

SWOT snapshot

Strengths

  • Financially solid — Altman Z 9.11.

Opportunities

  • Earnings growing (72% YoY).
  • Revenue growing (18% YoY).

Threats

  • Rich valuation versus sector peers.

About Aster DM Healthcare Ltd.

Aster DM Healthcare Limited, together with its subsidiaries, provides healthcare services in India. It operates through Hospitals, Clinics, Wholesale Pharmacies, and Others segments. The company operates hospitals, clinic, and in-house pharmacies at the hospitals and clinics

More in Healthcare

Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.